Dosage Adjustments in Patients with CLcr Less Than 60 mL/min Including Patients Receiving Intermittent HD
Dosage adjustment of FETROJA is recommended in patients with CLcr less than 60 mL/min (Table 1). For patients undergoing intermittent HD, start the dosing of FETROJA immediately after the completion of HD. For patients with fluctuating renal function, monitor CLcr and adjust dosage accordingly.
Table 1 Recommended Dosage of FETROJA for Patients with CLcr Less Than 60 mL/min Including Patients Receiving Intermittent HD| Estimated Creatinine Clearance (CLcr)
CLcr = creatinine clearance estimated by Cockcroft-Gault equation. | Dose | Frequency | Infusion Time |
|---|
| HD = hemodialysis. |
| CLcr 30 to 59 mL/min | 1.5 grams | Every 8 hours | 3 hours |
| CLcr 15 to 29 mL/min | 1 gram | Every 8 hours | 3 hours |
| CLcr less than 15 mL/min, with or without intermittent HD
Cefiderocol is removed by HD; administer FETROJA immediately after HD for patients receiving intermittent HD. | 0.75 grams | Every 12 hours | 3 hours |
Dosage Adjustments in Patients Receiving CRRT
For patients receiving CRRT, including continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF), the dosage of FETROJA should be based on the effluent flow rate in CRRT (see
Table 2). These recommendations are intended to provide initial dosing in patients receiving CRRT. Dosing regimens may need to be tailored based on residual renal function and patient's clinical status
[see
Use in Specific Populations (8.6)]
.
Table 2 Recommended Dosage of FETROJA for Patients Receiving CRRT| Effluent Flow Rate
Ultrafiltrate flow rate for CVVH, dialysis flow rate for CVVHD, ultrafiltrate flow rate plus dialysis flow rate for CVVHDF. | Recommended Dosage of FETROJA |
|---|
| CRRT = continuous renal replacement therapy. |
| 2 L/hr or less | 1.5 grams every 12 hours |
| 2.1 to 3 L/hr | 2 grams every 12 hours |
| 3.1 to 4 L/hr | 1.5 grams every 8 hours |
| 4.1 L/hr or greater | 2 grams every 8 hours |
Dosage Adjustments in Patients with CLcr 120 mL/min or Greater
For patients with CLcr greater than or equal to 120 mL/min, FETROJA 2 grams administered every 6 hours by IV infusion over 3 hours is recommended
[see
Use in Specific Populations (8.6)]
.
Preparation of Doses
Reconstitute the powder for injection in the FETROJA vial with 10 mL of either 0.9% sodium chloride injection, USP or 5% dextrose injection, USP and gently shake to dissolve. Allow the vial(s) to stand until the foaming generated on the surface has disappeared (typically within 2 minutes). The reconstituted solution will have a final volume of approximately 11.2 mL and concentration of 0.089 gram/mL. The reconstituted solution is for intravenous infusion only after dilution in an appropriate infusion solution.
To prepare the required doses, withdraw the appropriate volume of reconstituted solution from the vial according to Table 3 below. Add the withdrawn volume to a 100 mL infusion bag containing 0.9% sodium chloride injection, USP or 5% dextrose injection, USP
[see
Dosage and Administration (2.4)]
.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. FETROJA infusions are clear, colorless solutions. Discard any unused FETROJA solution in the vial (see
Table 3).
Table 3 Preparation of FETROJA Doses| FETROJA Dose | Number of 1-gram FETROJA Vials to be Reconstituted | Volume to Withdraw from Reconstituted Vial(s) | Total Volume of FETROJA Reconstituted Solution for Further Dilution into a 100 mL Infusion Bag |
|---|
| 2 grams | 2 vials | 11.2 mL (entire contents) of each vial | 22.4 mL |
| 1.5 grams | 2 vials | 11.2 mL (entire contents) of first vial AND 5.6 mL from second vial | 16.8 mL |
| 1 gram | 1 vial | 11.2 mL (entire contents) | 11.2 mL |
| 0.75 gram | 1 vial | 8.4 mL | 8.4 mL |
Reconstituted FETROJA
Upon reconstitution with the appropriate diluent, the reconstituted FETROJA solution in the vial should be immediately transferred and diluted into the infusion bag. Reconstituted FETROJA can be stored for up to 1 hour at room temperature in the vial. Discard any unused reconstituted solution.
Diluted FETROJA Infusion Solution
The diluted FETROJA infusion solution in the infusion bag is stable for up to 6 hours at room temperature.
The diluted FETROJA infusion solution in the infusion bag may also be refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours, protected from light; and then the infusion should be completed within 6 hours at room temperature.
Complicated Urinary Tract Infections (cUTIs), Including Pyelonephritis
FETROJA was evaluated in an active-controlled, randomized clinical trial in patients with cUTI, including pyelonephritis (Trial 1). In this trial, 300 patients received FETROJA 2 grams every 8 hours infused over 1 hour (or a renally-adjusted dose), and 148 patients were treated with imipenem/cilastatin 1gram/1gram every 8 hours infused over 1 hour (or a renally-adjusted dose). The median age of treated patients across treatment arms was 65 years (range 18 to 93 years), with approximately 53% of patients aged greater than or equal to 65. Approximately 96% of patients were White, most were from Europe, and 55% were female. Patients across treatment arms received treatment for a median duration of 9 days.
Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
In Trial 1, a total of 14/300 (4.7%) cUTI patients treated with FETROJA and 12/148 (8.1%) of cUTI patients treated with imipenem/cilastatin experienced serious adverse reactions. One death (0.3%) occurred in 300 patients treated with FETROJA as compared to none treated with imipenem/cilastatin. Discontinuation of treatment due to any adverse reaction occurred in 5/300 (1.7%) of patients treated with FETROJA and 3/148 (2.0%) of patients treated with imipenem/cilastatin. Specific adverse reactions leading to treatment discontinuation in patients who received FETROJA included diarrhea (0.3%), drug hypersensitivity (0.3%), and increased hepatic enzymes (0.3%).
Common Adverse Reactions
Table 4 lists the most common selected adverse reactions occurring in ≥ 2% of cUTI patients receiving FETROJA in Trial 1.
Table 4 Selected Adverse Reactions Occurring in ≥ 2% of cUTI Patients Receiving FETROJA in Trial 1| Adverse Reaction | FETROJA
2 grams IV over 1 hour every 8 hours (with dosing adjustment based on renal function). (N = 300)
| Imipenem/Cilastatin
1 gram IV over 1 hour every 8 hours (with dosing adjustment based on renal function and body weight). (N = 148)
|
|---|
| cUTI = complicated urinary tract infection. |
| Diarrhea | 4% | 6% |
| Infusion site reactions
Infusion site reactions include infusion site erythema, inflammation, pain, pruritus, injection site pain, and phlebitis. | 4% | 5% |
| Constipation | 3% | 4% |
| Rash
Rash includes rash macular, rash maculopapular, erythema, skin irritation. | 3% | < 1% |
| Candidiasis
Candidiasis includes oral or vulvovaginal candidiasis, candiduria. | 2% | 3% |
| Cough | 2% | < 1% |
| Elevations in liver tests
Elevations in liver tests include alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, blood alkaline phosphatase, hepatic enzyme increased. | 2% | < 1% |
| Headache | 2% | 5% |
| Hypokalemia
Hypokalemia includes blood potassium decreased. | 2% | 3% |
| Nausea | 2% | 4% |
| Vomiting | 2% | 1% |
Other Adverse Reactions of FETROJA in the cUTI Patients (Trial 1)
The following selected adverse reactions were reported in FETROJA-treated cUTI patients at a rate of less than 2% in Trial 1:
Blood and lymphatic disorders: thrombocytosis
Cardiac disorders: congestive heart failure, bradycardia, atrial fibrillation
Gastrointestinal disorders: abdominal pain, dry mouth, stomatitis
General system disorders: pyrexia, peripheral edema
Hepatobiliary disorders: cholelithiasis, cholecystitis, gallbladder pain
Immune system disorders: drug hypersensitivity
Infections and infestations:
C. difficileinfection
Laboratory investigations: prolonged prothrombin time (PT) and prothrombin time international normalized ratio (PT-INR), red blood cells urine positive, creatine phosphokinase increase
Metabolism and nutrition disorders: decreased appetite, hypocalcemia, fluid overload
Nervous system disorders: dysgeusia, seizure
Respiratory, thoracic, and mediastinal disorders: dyspnea, pleural effusion
Skin and subcutaneous tissue disorders: pruritus
Psychiatric disorders: insomnia, restlessness
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)
FETROJA was evaluated in an active-controlled clinical trial in patients with HABP/VABP (Trial 2). In this trial, 148 patients received FETROJA 2 grams every 8 hours infused over 3 hours, and 150 patients received meropenem 2 grams every 8 hours infused over 3 hours. Doses of study treatments were adjusted based on renal function. The median age was 67 years, approximately 59% of patients were 65 years of age and older, 69% were male, and 68% were White. Overall, approximately 60% were ventilated at randomization, including 41% with VABP and 14% with ventilated HABP. The mean Acute Physiology And Chronic Health Evaluation (APACHE II) score was 16. All patients received empiric treatment for Gram-positive organisms with linezolid for at least 5 days.
Serious Adverse Reactions and Adverse Reactions Leading to Discontinuation
In Trial 2, serious adverse reactions occurred in 54/148 (36.5%) HABP/VABP patients treated with FETROJA and 45/150 (30%) of HABP/VABP patients treated with meropenem. Adverse reactions leading to death were reported in 39/148 (26.4%) patients treated with FETROJA and 35/150 (23.3%) patients treated with meropenem. Adverse reactions leading to discontinuation of treatment occurred in 12/148 (8.1%) of patients treated with FETROJA and 14/150 (9.3%) of patients treated with meropenem. The most common adverse reactions leading to discontinuation in both treatment groups were elevated liver tests.
Common Adverse Reactions
Table 5 lists the most common selected adverse reactions occurring in ≥ 4% of patients receiving FETROJA in the HABP/VABP trial.
Table 5 Selected Adverse Reactions Occurring in ≥ 4% of HABP/VABP Patients Receiving FETROJA in Trial 2| Adverse Reaction | FETROJA
2 grams IV over 3 hours every 8 hours (with dosing adjustment based on renal function). N = 148
| Meropenem
2 grams IV over 3 hours every 8 hours (with dosing adjustment based on renal function). N = 150
|
|---|
| HABP/VABP = hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. |
| Elevations in liver tests
Elevations in liver tests include the following terms: aspartate aminotransferase increased, alanine aminotransferase increased, gamma-glutamyl transferase increased, liver function test increased, liver function test abnormal, hepatic enzyme increased, transaminases increased, hypertransaminesemia. | 16% | 16% |
| Hypokalemia
Hypokalemia includes blood potassium decreased. | 11% | 15% |
| Diarrhea | 9% | 9% |
| Hypomagnesemia | 5% | < 1% |
| Atrial fibrillation | 5% | 3% |
Other Adverse Reactions of FETROJA in HABP/VABP Patients in Trial 2
The following selected adverse reactions were reported in FETROJA-treated HABP/VABP patients at a rate of less than 4% in Trial 2:
Blood and lymphatic disorders: thrombocytopenia, thrombocytosis
Cardiac disorders: myocardial infarction, atrial flutter
Gastrointestinal disorders: nausea, vomiting, abdominal pain
Hepatobiliary disorders: cholecystitis, cholestasis
Infections and infestations:
C. difficileinfection, oral candidiasis
Laboratory investigations: prolonged prothrombin time (PT) and prothrombin time international normalized ratio (PT-INR), activated partial thromboplastin time (aPTT)
Metabolism and nutrition disorders: hypocalcemia, hyperkalemia
Nervous system disorders: seizure
Renal and genitourinary disorders: acute interstitial nephritis
Respiratory, thoracic, and mediastinal disorders: cough
Skin and subcutaneous tissue disorders: rash including rash erythematous
Risk Summary
There are no available data on FETROJA use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Available data from published prospective cohort studies, case series, and case reports over several decades with cephalosporin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
(see
Data)
.
Developmental toxicity studies with cefiderocol administered during organogenesis to rats and mice showed no evidence of embryo-fetal toxicity, including drug-induced fetal malformations, at doses providing exposure levels 0.9 times (rats) or 1.3 times (mice) higher than the average observed in patients receiving the maximum recommended daily dose.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data
Human Data
While available studies cannot definitively establish the absence of risk, published data from prospective cohort studies, case series, and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups.
Animal Data
Developmental toxicity was not observed in rats at intravenous doses of up to 1000 mg/kg/day or mice at subcutaneous doses of up to 2000 mg/kg/day given during the period of organogenesis (gestation days 6-17 in rats and 6-15 in mice). No treatment-related malformations or reductions in fetal viability were observed. Mean plasma exposure (AUC) at these doses was approximately 0.9 times (rats) and 1.3 times (mice) the daily mean plasma exposure in patients that received 2 grams of cefiderocol infused intravenously every 8 hours.
In a pre- and postnatal development study, cefiderocol was administered intravenously at doses up to 1000 mg/kg/day to rats from Day 6 of pregnancy until weaning. No adverse effects on parturition, maternal function, or pre- and postnatal development and viability of the pups were observed.
In pregnant rats, cefiderocol-derived radioactivity was shown to cross the placenta, but the amount detected in fetuses was a small percentage (< 0.5%) of the dose.
Risk Summary
It is not known whether cefiderocol is excreted into human milk; however, cefiderocol-derived radioactivity was detected in the milk of lactating rats that received the drug intravenously. When a drug is present in animal milk, it is likely that the drug will be present in human milk. No information is available on the effects of FETROJA on the breastfed infant or on milk production.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for FETROJA and any potential adverse effects on the breastfed child from FETROJA or from the underlying maternal condition.
Data
Cefiderocol-derived radioactivity was detected in milk following intravenous administration to lactating rats. The peak level in rat milk was approximately 6% of the peak plasma level.
cUTI
Of the 300 patients treated with FETROJA in the cUTI trial, 158 (52.7%) were 65 years of age and older, and 67 (22.3%) were 75 years of age and older. No overall differences in safety or efficacy were observed between these patients and younger patients.
HABP/VABP
Of the 148 patients treated with FETROJA in the HABP/VABP trial, 83 (56.1%) were 65 years of age and older, and 40 (27%) were 75 years of age and older.
The incidence of adverse reactions in patients treated with FETROJA was similar in patients under 65 years of age as compared to older patients (65 years of age and older and 75 years of age and older). The incidence of adverse reactions in older patients (65 years of age and older and 75 years of age and older) was also similar between treatment groups.
Clinical cure rates at the Test-of-Cure visit (TOC) in FETROJA-treated adult patients younger than 65 years of age, 65 years of age to younger than 75 years of age, and 75 years of age and older were 60%, 77.5%, and 60%, respectively. In comparison, the clinical cure rates at the TOC visit in the meropenem-treated patients for each of these subgroups were 65.5%, 64.4%, and 70.5%, respectively. The observed all-cause mortality rates at Day 14 in the FETROJA-treated patients for each of these subgroups were 12.3%, 7.5%, and 17.5%, respectively. In comparison, in the meropenem-treated patients for each of these subgroups, they were 10.3%, 17.8%, and 9.1%, respectively.
cUTI and HABP/VABP
FETROJA is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. No dosage adjustment is required based on age. Dosage adjustment for elderly patients should be based on renal function
[see
Dosage and Administration (2.2),
Use in Specific Populations (8.6), and
Clinical Pharmacology (12.3)]
.
Patients with CLcr 60 to 89 mL/min
No dosage adjustment of FETROJA is recommended in patients with CLcr 60 to 89 mL/min.
Patients with CLcr Less Than 60 mL/min Including Patients Receiving Intermittent HD
Dose adjustment is required in patients with CLcr less than 60 mL/min, and in patients who are receiving HD. In patients requiring HD, complete HD at the latest possible time before the start of cefiderocol dosing
[see
Dosage and Administration (2.2)and
Clinical Pharmacology (12.3)]
. Monitor renal function regularly and adjust the dosage of FETROJA accordingly as renal function may change during the course of therapy.
Patients Receiving CRRT
A total of 16 patients treated with FETROJA received CRRT in clinical trials. Dosage adjustment of FETROJA is required in patients receiving CRRT including CVVH, CVVHD, and CVVHDF. Dosage of FETROJA should be based on the effluent flow rate in patients receiving CRRT
[see
Dosage and Administration (2.2)and
Clinical Pharmacology (12.3)].
While on CRRT, a patient's residual renal function may change. Improvements or reductions in residual renal function may warrant a change in FETROJA dosage.
Patients with CLcr 120 mL/min or Greater
CLcr 120 mL/min or greater may be seen in seriously ill patients, who are receiving intravenous fluid resuscitation. Dosage adjustment of FETROJA is required in patients with CLcr 120 mL/min or greater
[see
Dosage and Administration (2.2)and
Clinical Pharmacology (12.3)].
Monitor renal function regularly and adjust the dosage of FETROJA accordingly as renal function may change during the course of therapy.
Cardiac Electrophysiology
At doses 1 and 2 times the maximum recommended dosage, FETROJA does not prolong the QT interval to any clinically relevant extent.
Distribution
The geometric mean (±SD) cefiderocol volume of distribution was 18.0 (±3.36) L. Plasma protein binding, primarily to albumin, of cefiderocol is 40% to 60%.
Following a FETROJA 2-gram dose (or renal function equivalent dose) at steady state in patients with pneumonia requiring mechanical ventilation with a 3-hour infusion, the cefiderocol concentrations in epithelial lining fluid ranged from 3.1 to 20.7 mg/L and 7.2 to 15.9 mg/L at the end of infusion and at 2 hours after the end of infusion, respectively.
Elimination
Cefiderocol terminal elimination half-life is 2 to 3 hours. The geometric mean (±SD) cefiderocol clearance is estimated to be 5.18 (±0.89) L/hr.
Metabolism
Cefiderocol is minimally metabolized [less than 10% of a single radiolabeled cefiderocol dose of 1 gram (0.5 times the approved recommended dosage) infused over 1 hour].
Excretion
Cefiderocol is primarily excreted by the kidneys. After a single radiolabeled cefiderocol 1-gram (0.5 times the approved recommended dosage) dose infused over 1 hour, 98.6% of the total radioactivity was excreted in urine (90.6% unchanged) and 2.8% in feces.
Specific Populations
No clinically significant differences in the pharmacokinetics of cefiderocol were observed based on age (18 to 93 years of age), sex, or race. The effect of hepatic impairment on the pharmacokinetics of cefiderocol was not evaluated.
Patients with Renal Impairment
Approximately 60% of cefiderocol was removed by a 3- to 4-hour hemodialysis session.
Cefiderocol AUC fold changes in subjects with renal impairment compared to subjects with CLcr 90 to 119 mL/min are summarized in Table 7.
Table 7 Effect of Renal Impairment on the AUC of Cefiderocol
After a single FETROJA 1-gram dose (0.5 times the approved recommended dosage).
| CLcr (mL/min) | Cefiderocol AUC
Geometric Mean Ratios (90% CI)
Compared to AUC in subjects with CLcr 90 to 119 mL/min (N = 12). |
|---|
| CI = confidence interval. |
| 60 to 89 (N = 6) | 1.37 (1.15, 1.62) |
| 30 to 59 (N = 7) | 2.35 (2.00, 2.77) |
| 15 to 29 (N = 4) | 3.21 (2.64, 3.91) |
| < 15 (N = 6) | 4.69 (3.95, 5.56) |
Patients Receiving CRRT
In an
in vitro study, effluent flow rate was the major determinant of cefiderocol clearance by CRRT. Variables examined included effluent flow rate, CRRT mode (CVVH or CVVHD), filter type and point of dilution (pre- or post-filter dilution). The effluent flow rate-based dosing recommendations in Table 2 are predicted to provide cefiderocol exposures similar to those achieved with a dose of 2 grams given every 8 hours in patients not receiving CRRT
[see
Dosage and Administration (2.2)]
.
Patients with CLcr 120 mL/min or Greater
Increased cefiderocol clearance has been observed in patients with CLcr 120 mL/min or greater. A FETROJA 2-gram dose every 6 hours infused over 3 hours provided cefiderocol exposures comparable to those in patients with CLcr 90 to 119 mL/min
[see
Dosage and Administration (2.2)]
.
Drug Interaction Studies
Clinical Studies
No clinically significant differences in the pharmacokinetics of furosemide (an organic anion transporter [OAT]1 and OAT3 substrate), metformin (an organic cation transporter [OCT]1, OCT2, and multidrug and toxin extrusion [MATE]2-K substrate), and rosuvastatin (an organic anion transporting polypeptide [OATP]1B3 substrate) were observed when coadministered with cefiderocol.
In Vitro Studies Where Drug Interaction Potential Was Not Further Evaluated Clinically
Cytochrome P450 (CYP) Enzymes: Cefiderocol is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. Cefiderocol is not an inducer of CYP1A2, CYP2B6, or CYP3A4.
Transporter Systems: Cefiderocol is not an inhibitor of OATP1B1, MATE1, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), or bile salt export pump transporters. Cefiderocol is not a substrate of OAT1, OAT3, OCT2, MATE1, MATE2-K, P-gp, or BCRP.
Mechanism of Action
FETROJA is a cephalosporin antibacterial with activity against Gram-negative aerobic bacteria. Cefiderocol functions as a siderophore and binds to extracellular free (ferric) iron. In addition to passive diffusion via porin channels, cefiderocol is actively transported across the outer cell membrane of bacteria into the periplasmic space using the bacterial siderophore iron uptake mechanism. Cefiderocol exerts bactericidal action by inhibiting cell wall biosynthesis through binding to penicillin-binding proteins (PBPs).
Cefiderocol has no clinically relevant
in vitro activity against most Gram-positive bacteria and anaerobic bacteria.
Resistance
In vitro, MIC increases that may result in resistance to cefiderocol in Gram-negative bacteria have been associated with a combination of multiple beta-lactamases, modifications of PBPs, and mutations of transcriptional regulators that impact siderophore expression.
Cefiderocol does not cause induction of AmpC beta-lactamase in
P. aeruginosa and
E. cloacae. The frequency of resistance development in Gram-negative bacteria including carbapenemase producers exposed to cefiderocol at 10× minimum inhibitory concentration (MIC) ranged from 10
-6 to < 10
-8.
Cross-resistance with other classes of antibacterial drugs has not been identified; therefore, isolates resistant to other antibacterial drugs may be susceptible to cefiderocol.
Cefiderocol has shown
in vitro activity against isolates of
S. maltophilia and a subset of isolates of Enterobacterales and
P. aeruginosa that are resistant to meropenem, ciprofloxacin, amikacin, cefepime, ceftazidime-avibactam, and ceftolozane/tazobactam
. Cefiderocol has shown
in vitro activity against subset of isolates of
A. baumannii complex that are resistant to meropenem, ciprofloxacin, and amikacin
.Cefiderocol is active against some colistin-resistant
E. coli isolates containing
mcr-1.
Cefiderocol demonstrated
in vitro activity against a subgroup of Enterobacterales genetically confirmed to contain the following: ESBLs (TEM, SHV, CTX-M, oxacillinase [OXA]), AmpC, AmpC-type ESBL (CMY), serine-carbapenemases (such as KPC, OXA-48), and metallo-carbapenemases (such as NDM and VIM). Cefiderocol demonstrated
in vitro activity against a subgroup of
P. aeruginosa genetically confirmed to contain VIM, IMP, GES, AmpC, and a subgroup of
A. baumannii containing OXA-23, OXA-24/40, OXA-51, OXA-58, and AmpC. Cefiderocol is active
in vitro against a subgroup of
S. maltophilia containing metallo-carbapenemase (L1) and serine beta-lactamases (L2).
Cefiderocol maintained
in vitro activity against
K. pneumoniae in the presence of porin channel deletions (OmpK35/36), and against
P. aeruginosa in the presence of porin channel deletions (OprD) and efflux pump up-regulation (MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY).
In vitro, the addition of the beta-lactamase inhibitors (such as avibactam, clavulanic acid, and dipicolinic acid) results in the lowering of MICs of some clinical isolates with relatively high MICs (range 2 to 256 mcg/mL) to cefiderocol.
Interaction with Other Antimicrobials
In vitro studies showed no antagonism between cefiderocol and amikacin, ceftazidime/avibactam, ceftolozane/tazobactam, ciprofloxacin, clindamycin, colistin, daptomycin, linezolid, meropenem, metronidazole, tigecycline, or vancomycin against strains of Enterobacterales,
P. aeruginosa, and
A. baumannii.
Activity against Bacteria in Animal Infection Models
In a neutropenic murine thigh infection model using a humanized dose (2 grams every 8 hours), cefiderocol demonstrated 1log
10 reduction in bacterial burden against most
E. coli, K. pneumoniae,
A. baumannii,
S. maltophilia,and
P. aeruginosa including some carbapenemase-producing (KPC, OXA-23, OXA-24/40, OXA-58) isolates with MICs of ≤ 4 mcg/mL to cefiderocol.
In an immunocompetent rat pneumonia model, reduction in bacterial counts in the lungs of animals infected with
K. pneumoniae with MICs ≤ 8 mcg/mL,
A. baumanniiwith MICs ≤ 2 mcg/mL
,and
P. aeruginosawith MICs ≤ 1 mcg/mL including carbapenemase-producing (KPC, NDM, and IMP) isolates was observed using humanized cefiderocol drug exposure.
In an immunocompetent murine urinary tract infection model, cefiderocol reduced bacterial counts in the kidneys of mice infected with
E. coli, K. pneumoniae, and
P. aeruginosa isolates with MICs ≤ 1 mcg/mL. In an immunocompromised murine systemic infection model, cefiderocol increased survival in mice infected with
E. cloacae,
S. maltophilia, and
Burkholderia cepacia isolates with MICs ≤ 0.5 mcg/mL compared to untreated mice. In an immunocompetent murine systemic infection model, cefiderocol increased survival in mice infected with
S. marcescens and
P. aeruginosa isolates with MICs ≤ 1 mcg/mL compared to untreated mice.
The clinical significance of the above findings in animal infection models is not known.
Antimicrobial Activity
FETROJA has been shown to be active against the following bacteria, both
in vitro and in clinical infections
[see
Indications and Usage (1)]
:
Complicated Urinary Tract Infections, Including Pyelonephritis
Gram-negative Bacteria
Escherichia coli
Enterobacter cloacae complex
Klebsiella pneumoniae
Proteus mirabilis
Pseudomonas aeruginosa
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP)
Gram-negative Bacteria
Acinetobacter baumannii complex
Escherichia coli
Enterobacter cloacae complex
Klebsiella pneumoniae
Pseudomonas aeruginosa
Serratia marcescens
The following
in vitro data are available, but their clinical significance is not known. At least 90% of the following bacteria exhibit an
in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for FETROJA against isolates of similar genus or organism group. However, the efficacy of FETROJA in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.
Gram-negative Bacteria
Achromobacter spp.
Burkholderia cepacia complex
Citrobacter freundii complex
Citrobacter koseri
Klebsiella aerogenes
Klebsiella oxytoca
Morganella morganii
Proteus vulgaris
Providencia rettgeri
Stenotrophomonas maltophilia
Susceptibility Testing
For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see https://www.fda.gov/STIC.
Carcinogenesis
Carcinogenicity studies in animals have not been conducted with cefiderocol.
Mutagenesis
Cefiderocol was negative for genotoxicity in a reverse mutation test with
S. typhimurium and
E. coliand did not induce mutations in V79 Chinese hamster lung cells. Cefiderocol was positive in a chromosomal aberration test in cultured TK6 human lymphoblasts and increased mutation frequency in L5178Y mouse lymphoma cells. Cefiderocol was negative in an
in vivo rat micronucleus test and a rat comet assay at the highest doses of 2000 and 1500 mg/kg/day, respectively.
Impairment of Fertility
Cefiderocol did not affect fertility in adult male or female rats when administered intravenously at doses up to 1000 mg/kg/day. The AUC at this dose is approximately 0.9 times the mean daily cefiderocol exposure in patients who received the maximum recommended clinical dose of 2 grams every 8 hours.
Serious Allergic Reactions
Advise patients and their families that allergic reactions, including serious allergic reactions, could occur with FETROJA and that serious reactions require immediate treatment. Ask patients about any previous hypersensitivity reactions to FETROJA, other beta-lactams (including cephalosporins), or other allergens
[see
Warnings and Precautions (5.2)]
.
Potentially Serious Diarrhea
Advise patients and their families that diarrhea is a common problem caused by antibacterial drugs, including FETROJA. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, tell patient to contact his or her healthcare provider
[see
Warnings and Precautions (5.3)]
.
Seizures
Counsel patients on the implication of cephalosporins, including FETROJA, in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced and in patients with a history of epilepsy
[see
Warnings and Precautions (5.4)]
.
Antibacterial Resistance
Patients should be counseled that antibacterial drugs including FETROJA should only be used to treat bacterial infections. They do not treat viral infections (e.g., influenza, common cold). When FETROJA is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by FETROJA or other antibacterial drugs in the future
[see
Warnings and Precautions (5.5)]
.
Manufactured by
Shionogi & Co., Ltd.
Osaka 541-0045
Japan
Manufactured for
Shionogi Inc.
Florham Park, NJ
USA, 07932